Diligence memo · auto-generated · as of July 3, 2026

Femmepharma Holding Co Inc

Femmepharma Holding Co Inc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Femmepharma Holding Co Inc operates in Pharmaceuticals, based in WAYNE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Femmepharma Holding Co Inc has raised $2.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.4M on 2010-03-31.

Most recent recorded round closed around 2011-09-01.

Valuation (modeled)modeled

Provath models Femmepharma Holding Co Inc at approximately $26M (range $515K–$203M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.43× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 14.8 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 28% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 32% of those peers.

Closest niche peers: First China Pharmaceutical Group, Inc., MediQuest Holdings LLC, Ampla Pharmaceuticals Inc, Biomimetix Pharmaceutical, Inc., Prexa Pharmaceuticals Inc.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.